News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

California Stem Cell, Inc. and Families Of Spinal Muscular Atrophy Announce Completion of Pre-IND Meeting with FDA for Stem Cell-Derived Therapy for the Treatment of Spinal Muscular Atrophy Type I


10/14/2009 9:30:12 AM

IRVINE, Calif.--(BUSINESS WIRE)--California Stem Cell, Inc. (CSC) and Families of Spinal Muscular Atrophy (FSMA) announced today that they have completed a formal pre-Investigational New Drug (Pre-IND) meeting with the Food and Drug Administration (FDA) for guidance on the clinical and regulatory pathway and requirements for submission of an IND to initiate human trials for a stem cell-derived motor neuron replacement therapy for Spinal Muscular Atrophy (SMA) Type I.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES